Indications 1.Medium to late stage central and peripheral lung cancer as the main target; 2.Those who can be surgically resected but have contraindications to surgery or refuse surgery; 3.Those who need local chemotherapy to improve the efficacy before surgery; 4.Small cell lung cancer patients who do not receive systemic chemotherapy; 5.Those who do not receive systemic chemotherapy although they have metastases inside and outside the chest. Contraindications 1.Cachexia or heart, lung, liver and kidney failure; 2.High fever, severe infection or significantly low white blood cell count (less than 3×109/L); 3.Severe bleeding tendency and iodine allergy and other angiographic contraindications. Preoperative preparation 1. Definite diagnosis: a. routine chest X-ray, enhanced CT to clarify tumor size, location, number, tumor supply artery (CTA); b. CT or MR of head, abdomen, pelvis, PET-CT if necessary to clarify whether there is metastasis; c. sputum, tracheoscopy or thoracic or percutaneous aspiration to obtain histological diagnosis; d. laboratory tests: routine blood, clotting time, liver and kidney function, neuronal specific enolase (NSE, lung cancer specific index) 2. Patient preparation: conversation signature; iodine allergy test; four-hour preoperative fast. Technical operation 1.Search for blood supply arteries such as bronchial arteries, see embolization therapy for hemoptysis. 2.Bronchial artery infusion chemotherapy (BAI) Referring to the scheme of systemic chemotherapy, it is recommended to use platinum plus gemcitabine or paclitaxel, etc. as the main diphtherapy, and the recommended dosage is no more than two-thirds of the total amount of intravenous chemotherapy. The drug is diluted and slowly pushed through the artery, or an arterial pump can be used to maintain the drip for 1-2 hours via catheter. If the overall condition of the patient is poor, the dosage of chemotherapy drugs can be reduced as appropriate. 3.Bronchial artery embolization (BAE) The tumor is rich in blood supply, the blood supply artery is thick or there is bronchial artery-pulmonary artery or pulmonary vein fistula and there is no spinal nutritive artery and head and neck traffic branch or can be super-selected to avoid. Under fluoroscopy, the mixture of gelatin sponge pellets and contrast medium should be slowly pushed through the catheter and stopped when the flow rate slows down significantly to avoid regurgitation or excessive embolization of the trunk causing permanent occlusion. Complication prevention and management See Treatment of hemoptysis for details. It should be emphasized that due to the chemical toxicity of chemotherapeutic agents, the possibility of spinal cord injury and tracheobronchial or esophageal injury during bronchial artery chemoperfusion is much higher than that of embolization alone during hemoptysis treatment, and in addition, the possibility of skin death can occur during chemoperfusion of the internal mammary and intercostal arteries. Therefore, adequate dilution of chemotherapeutic agents and slow perfusion should be performed, with more use of microcatheterization and protective embolization techniques. The efficacy of BAE+BAI is better than that of BAI due to the difference in case selection, chemotherapy drugs and dosage, the pathological type of tumor, the number of interventions and the operating ability of the interventional staff, etc. The efficacy of CR+PR is 51.5~86.0%, and the 1-year survival rate is 58.8~67%, which are higher than that of systemic chemotherapy alone. The efficacy rate was between 50 and 9O%.